Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor vaccination

P Mallmann1

  • 1Department of Gynecology and Obstetrics, University of Bonn, Germany.

Hybridoma
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

Active specific immunotherapy using tumor vaccination can induce immune responses against cancer. Viral xenogenization shows promise, with benefits observed in ovarian cancer patients when combined with pre-treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Menopausal hormone therapy and breast cancer risk].

Der Internist·2020
Same author

Breast conserving surgery in combination with intraoperative radiotherapy after previous external beam therapy: an option to avoid mastectomy.

Breast cancer research and treatment·2018
Same author

Technologies of cryoprotectant-free vitrification of human spermatozoa: asepticity as criterion of effectiveness.

Andrology·2017
Same author

Use of the fluorescent dye tetramethylrhodamine methyl ester perchlorate for mitochondrial membrane potential assessment in human spermatozoa.

Andrologia·2017
Same author

Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Geburtshilfe und Frauenheilkunde·2016
Same author

Induction of Labour in Late and Postterm Pregnancies and its Impact on Maternal and Neonatal Outcome.

Geburtshilfe und Frauenheilkunde·2016
Same journal

A monoclonal antibody specific for Pseudomonas aeruginosa amidase.

Hybridoma·2001
Same journal

Characterization of monoclonal antibodies against carcinoembryonic antigen (CEA) and expression in E. coli.

Hybridoma·2001
Same journal

Generation and characterization of monoclonal antibodies against the E6 and E7 oncoproteins of HPV.

Hybridoma·2001
Same journal

Monoclonal antibodies against human telomerase reverse transcriptase (hTERT): preparation, characterization, and application.

Hybridoma·2001
Same journal

Evaluation of clinical significance of isoferritin by development of new monoclonal antibodies specific for acidic isoferritin.

Hybridoma·2001
Same journal

Production, characterization, and epitope mapping of monoclonal antibodies against human polydeoxyribonucleotide kinase.

Hybridoma·2001
See all related articles

Area of Science:

  • Oncology
  • Immunotherapy
  • Gynecologic Oncology

Background:

  • Tumor vaccination is an active immunotherapy strategy to elicit anti-tumor immune responses.
  • Research has explored native and modified tumor cells, with recent focus on viral xenogenization.
  • Pre-treatment of tumor-bearing hosts may improve vaccine efficacy and tumor cell susceptibility.

Purpose of the Study:

  • To evaluate the efficacy of tumor vaccination, particularly viral xenogenization, in gynecologic cancers.
  • To explore the potential benefits of combining chemo- and immunotherapy.

Main Methods:

  • Review of studies on tumor vaccination, including native, modified, and virally xenogenized tumor cells.
  • Analysis of clinical data from gynecologic cancer patients receiving tumor vaccination.

Related Experiment Videos

  • Investigation of pre-treatment strategies to enhance immunotherapy outcomes.

    • Main Results:

    • Tumor vaccination induced specific cytotoxicity in a subset of gynecologic cancer patients.
    • Ovarian cancer patients showed a potential benefit compared to historical controls.
    • Pre-treatment prior to vaccination may enhance immune reactivity and tumor cell susceptibility.

    Conclusions:

    • Tumor vaccination, especially viral xenogenization, is a viable immunotherapy approach for gynecologic cancers.
    • Combination therapy with pre-treatment strategies warrants further investigation for improved patient outcomes.